Trump pharma deals lure investment to US, Europe warns of exodus

Pharmaceutical firms warn that new U.S. deals under Trump are diverting investment away from Europe, threatening the region's drug-manufacturing base. The announcement signals a shift in transatlantic industrial competition, with Europe facing pressure to respond. Uncertainty remains over the scale of investment relocation and any EU countermeasures.